Trial · NCT05259696
Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)
NCT05259696, Phase 1, Phase 2, Completed, Palleon Pharmaceuticals, Inc.; results first posted 2025-08-20
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01). Trials, record NCT05259696. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05259696
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)
- NCT number
- NCT05259696
- Status
- Completed
- Phases
- Phase 1, Phase 2
- Enrollment
- 69 participants, actual
- Lead sponsor
- Palleon Pharmaceuticals, Inc.
- Conditions
Oncology, Melanoma, Ovarian Cancer, NSCLC, Non Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Cancer, CRC, Colon Cancer, Breast Cancer, Gastric Cancer, EGJ, Esophagogastric Junction Cancer, Head and Neck Cancer, Urothelial Cancer, Bladder Cancer
- Interventions
- E-602, Cemiplimab
- First posted
- 2022-02-28
- Last updated
- 2025-08-20
- Results first posted
- 2025-08-20
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants Who Experienced AEs or SAEs | 15 Months | Number of participants who experienced an adverse events (AEs) or a serious adverse event (SAE) |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants Who Experienced AEs or SAEs | 15 Months | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group12
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants Who Experienced AEs or SAEs | E-602 1 mg/kg | Participants with any Treatment Emergent AE | 5 | Participants | |
| Number of Participants Who Experienced AEs or SAEs | E-602 3 mg/kg | Participants with any Treatment Emergent AE | 4 | Participants | |
| Number of Participants Who Experienced AEs or SAEs | E-602 10 mg/kg | Participants with any Treatment Emergent AE | 8 | Participants | |
| Number of Participants Who Experienced AEs or SAEs | E-602 20 mg/kg | Participants with any Treatment Emergent AE | 15 | Participants | |
| Number of Participants Who Experienced AEs or SAEs | E-602 30 mg/kg | Participants with any Treatment Emergent AE | 15 | Participants | |
| Number of Participants Who Experienced AEs or SAEs | E-602 20 mg/kg in Combination With Cemiplimab | Participants with any Treatment Emergent AE | 20 | Participants | |
| Number of Participants Who Experienced AEs or SAEs | E-602 1 mg/kg | Participants with any Serious AE | 3 | Participants | |
| Number of Participants Who Experienced AEs or SAEs | E-602 3 mg/kg | Participants with any Serious AE | 1 | Participants | |
| Number of Participants Who Experienced AEs or SAEs | E-602 10 mg/kg | Participants with any Serious AE | 1 | Participants | |
| Number of Participants Who Experienced AEs or SAEs | E-602 20 mg/kg | Participants with any Serious AE | 6 | Participants |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 results by groupParticipant flow18
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | E-602 1 mg/kg | 5 | |
| Overall Study | STARTED | E-602 3 mg/kg | 4 | |
| Overall Study | STARTED | E-602 10 mg/kg | 9 | |
| Overall Study | STARTED | E-602 20 mg/kg | 15 | |
| Overall Study | STARTED | E-602 30 mg/kg | 15 | |
| Overall Study | STARTED | E-602 20 mg/kg in Combination With Cemiplimab | 21 | |
| Overall Study | COMPLETED | E-602 1 mg/kg | 5 | |
| Overall Study | COMPLETED | E-602 3 mg/kg | 4 | |
| Overall Study | COMPLETED | E-602 10 mg/kg | 9 | |
| Overall Study | COMPLETED | E-602 20 mg/kg | 15 |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 participant flowAdverse events354
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | E-602 1 mg/kg | 1 | 5 | |
| other | Anaemia | Blood and lymphatic system disorders | E-602 3 mg/kg | 0 | 4 | |
| other | Anaemia | Blood and lymphatic system disorders | E-602 10 mg/kg | 1 | 9 | |
| other | Anaemia | Blood and lymphatic system disorders | E-602 20 mg/kg | 6 | 15 | |
| other | Anaemia | Blood and lymphatic system disorders | E-602 30 mg/kg | 5 | 15 | |
| other | Anaemia | Blood and lymphatic system disorders | E-602 20 mg/kg in Combination With Cemiplimab | 1 | 21 | |
| other | Abdominal pain | Gastrointestinal disorders | E-602 1 mg/kg | 3 | 5 | |
| other | Abdominal pain | Gastrointestinal disorders | E-602 3 mg/kg | 1 | 4 | |
| other | Abdominal pain | Gastrointestinal disorders | E-602 10 mg/kg | 0 | 9 | |
| other | Abdominal pain | Gastrointestinal disorders | E-602 20 mg/kg | 2 | 15 |
1 to 10 of 354Source ClinicalTrials.gov
See all 354 adverse eventsAdverse event totals18
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | E-602 1 mg/kg | 5 | 5 |
| Total, all-cause mortality | E-602 3 mg/kg | 1 | 4 |
| Total, all-cause mortality | E-602 10 mg/kg | 7 | 9 |
| Total, all-cause mortality | E-602 20 mg/kg | 9 | 15 |
| Total, all-cause mortality | E-602 30 mg/kg | 6 | 15 |
| Total, all-cause mortality | E-602 20 mg/kg in Combination With Cemiplimab | 5 | 21 |
| Total, other adverse events | E-602 1 mg/kg | 5 | 5 |
| Total, other adverse events | E-602 3 mg/kg | 4 | 4 |
| Total, other adverse events | E-602 10 mg/kg | 8 | 9 |
| Total, other adverse events | E-602 20 mg/kg | 15 | 15 |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 adverse event totalsPapers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05259696
GET https://conductscience.org/api/trials/v1/NCT05259696/events?page=2